Edison Investment Research - Argos Therapeutics Inc (ARGS) QuickView: Second-generation dendritic cell therapy

Report

Edison Investment Research

QuickView: Second-generation dendritic cell therapy

Encouraging Phase II survival data at ASCO for Argos's lead product AGS-003 in mRCC have failed to move the stock from levels close to its 52-week low and below its IPO price in February 2014. While investors clearly remain cautious of dendritic cell transfer therapies, data expected mid-2014 (Phase IIb for AGS-004 in HIV) and at end 2015 (interim Phase III for AGS-003 in mRCC) could provide upside from the current EV of $71m.

17/07/2014 2 EN

Underlying

Argos Therapeutics Inc

See profile

US0402211033 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

BusinessWire

DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos Therapeutics, Inc. to Contact the Firm

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Argos Therapeutics, Inc. (Nasdaq: ARGS) (“Argos” or the “Company”) securities during the period between February 7, 2014 and February 21, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 15, 2...

April 20, 2017 April 20, 2017 1 EN

BusinessWire

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

March 28, 2017 March 28, 2017 1 EN

BusinessWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Argos Therapeutics, Inc. (NASDAQ:ARGS). On February 17, 2017, Momenta announced that a contracted Pfizer facility used to manufacture the Company's Glatopa product had received a warning letter from the U.S. Food and Drug Administration. The Company’s Abbreviated New Drug Application (ANDA) for its Glatopa 40 mg product candidate is still under regulatory review, with final approval reliant upon the acceptable resolution of the compliance obser...

February 22, 2017 February 22, 2017 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

April 19, 2024 April 19, 2024 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Second-generation dendritic cell therapy

DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos Therapeutics, Inc. to Contact the Firm

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics, Inc.

discoverIE Group - FY24 EPS in line; good margin progress

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe